A new bill proposes easing restrictions on cannabis research

There is a bipartisan initiative underway to encourage research into marijuana and other Schedule I chemicals. Dina Titus, Ilhan Omar and other representatives introduced the Evidence-Based Drug Policy Act of 2025 to eliminate barriers which currently prevent scientific studies of these substances. This bill aims to repeal certain sections of the Office of National Drug Control Policy Reauthorization act of 1998, which restrict federal funding of research for Schedule I drugs. The bill’s supporters argue that it is vital for understanding cannabis, its health effects and social consequences, as well as informing future policies. 

Drinks With THC Gain In Popularity Despite Ambiguous Regulation

In the United States there is a rapid expansion of THC-infused drink products. This has been fueled by changing laws as well as consumer demand. These drinks are usually derived from hemp and offer an alternative for traditional alcohol consumption. The regulatory environment remains complicated, however, because federal and state law differs on legality and classification. In 2018, the Farm Bill allowed hemp-derived products that contained less than 0.3% delta-9THC. However, synthetic cannabinoids have emerged and state laws vary. This has created a complex patchwork of regulations for manufacturers and consumers. 

Arizona Urgently recalls cannabis due to fungus contamination

Arizona Department of Health Services confirmed a recall of cannabis products due to contamination by Aspergillus. Aspergillus is a dangerous fungus which can be harmful, particularly for people with compromised immune systems. The Arizona Department of Health Services advises consumers to consult their healthcare provider if they used any of these recalled products. It is important to note that this incident highlights the need for strict quality controls in the cannabis sector.